Filter posts

Reimbursement Considerations for Early Stage Companies

Panelists at Tuesday’s breakout session – Reimbursement Considerations for Early Stage Companies – overwhelmingly agreed …

Convention Attendees Make the Call on Expanded Access

The BIO International Convention kicked off Monday with an interactive session organized by the BIO …

In Memory of Sandi Dennis

Last September, BIO and the industry lost a dear friend and one of the nation’s …

New NPC Report on Comparative Effectiveness Research

Advances in medical research create the potential for better health outcomes, improved treatment and even …

New Legislation Would Stimulate Investment in Innovation

Today, the Coalition of Small Business Innovators (CSBI) applauds Reps. Jim Gerlach (R-PA), Richard Neal …

Video: Emerging Company CEOs Praise JOBS Act

Passed in 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital …

San Francisco Business Times: Two JOBS Acts are better than one

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding …

SBIR Funds Speed the Delivery of Breakthrough Treatments and Cures

Today, BIO’s Executive Vice President of Emerging Companies Cartier Esham presented testimony to the U.S. …

Forbes: Sure, We'll (Eventually) Beat Cancer. But Can We Afford To?

On May 19, Paul Howard highlighted the promise of immunotherapy for the treatment and possible …

BIO Testifies at 21st Century Cures Hearing on PCAST

Today, BIO’s Executive Vice President of Health Sara Radcliffe presented testimony to the U.S. House …